OGN

Peers: VTRS BHC AMRX PRGO TEVA PFE ANIP ARQT PBH COLL

| Held by: IJR VTI VB VBR VXF SPSM IJS SLYV SCHA IWR

Index	-
Market Cap	3.61B
Enterprise Value	11.03B
Income	209.00M
Sales	6.13B
Book/sh	3.83
Cash/sh	4.31
Dividend Est.	0.08 (0.58%)
Dividend TTM	0.08 (0.58%)
Dividend Ex-Date	Aug 14, 2026
Dividend Gr. 3/5Y	-32.79% -
Payout	47.41%
Employees	10000
IPO	May 14, 2021

P/E	17.62
Forward P/E	3.79
PEG	1.23
P/S	0.59
P/B	3.59
P/C	3.19
P/FCF	6.37
EV/EBITDA	7.18
EV/Sales	1.80
Quick Ratio	1.44
Current Ratio	1.95
Debt/Eq	8.50
LT Debt/Eq	8.43
Option/Short	Yes / Yes

EPS (ttm)	0.78
EPS next Y	3.63
EPS next Q	0.88
EPS this Y	-8.47%
EPS next Y	8.36%
EPS next 5Y	3.09%
EPS past 3/5Y	-41.56% -39.04%
Sales past 3/5Y	0.23% -1.00%
EPS Y/Y TTM	-70.52%
Sales Y/Y TTM	-2.45%
EPS Q/Q	-28.36%
Sales Q/Q	-2.26%
Earnings	Aug 11
EPS/Sales Surpr.	-6.59% 0.00%

Insider Own	0.64%
Insider Trans	0.70%
Inst Own	83.25%
Inst Trans	-0.17%
ROA	1.57%
ROE	24.04%
ROIC	2.20%
Gross Margin	53.09%
Oper. Margin	19.41%
Profit Margin	3.41%
SMA20	0.06%
SMA50	0.18%
SMA200	21.46%
Trades

Shs Outstand	262.61M
Shs Float	260.93M
Short Float	7.27%
Short Ratio	7.07
Short Interest	18.96M
52W High	13.83 -0.56%
52W Low	5.69 141.70%
Volatility	0.30% 0.30%
ATR (14)	0.04
RSI (14)	53.34
Beta	1.53
Rel Volume	0.29
Avg Volume	2.68M
Volume	580,343

Perf Week	0.09%
Perf Month	0.38%
Perf Quarter	1.42%
Perf Half Y	50.47%
Perf YTD	91.81%
Perf Year	52.47%
Perf 3Y	-13.51%
Perf 5Y	-61.11%
Perf 10Y	-
Recom	3.00
Target Price	14.00
Prev Close	13.76
Price	13.75
Change %	-0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-26	Upgrade	Piper Sandler	Underweight → Neutral	$14
Dec-09-25	Initiated	Barclays	Underweight	$7.50
Oct-27-25	Downgrade	Piper Sandler	Overweight → Underweight	$5
May-02-25	Downgrade	Evercore ISI	Outperform → In-line
Sep-06-24	Downgrade	JP Morgan	Neutral → Underweight	$18 → $20
Nov-03-23	Downgrade	Goldman	Buy → Neutral	$33 → $16
Sep-21-23	Initiated	Barclays	Overweight	$28
Mar-16-23	Initiated	Raymond James	Outperform	$33
Oct-14-22	Downgrade	BofA Securities	Neutral → Underperform	$27 → $25
Sep-06-22	Upgrade	Piper Sandler	Neutral → Overweight	$37 → $34
Aug-05-22	Downgrade	BofA Securities	Buy → Neutral	$40 → $37
Apr-27-22	Initiated	Goldman	Buy	$40
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$35
Oct-07-21	Initiated	Piper Sandler	Neutral	$35
Sep-01-21	Initiated	BofA Securities	Buy	$43
Jul-22-21	Initiated	Citigroup	Buy	$35
Jun-15-21	Initiated	JP Morgan	Neutral	$38
Jun-11-21	Initiated	Morgan Stanley	Equal-Weight	$33
Jun-10-21	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Oct-19-26 07:30AM	Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing (Business Wire)
Oct-16-26 07:30AM	Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting (Business Wire)
Oct-01-26 08:00AM	Organon to Present New Real-World Analysis of VTAMA (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference (Business Wire)
Sep-14-26 07:30AM	Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA, a Hormone-Free Intrauterine Device (Business Wire)
Aug-11-26 07:30AM	Organon Opens REMS Program for MIUDELLA Ahead of Anticipated Commercial Availability (Business Wire)
08:41AM	Loading…
Jul-31-26 08:41AM	Organon: Q2 Earnings Snapshot (Associated Press)
08:30AM	Organon Announces Quarterly Dividend (Business Wire)
Jul-24-26 08:00AM	New Analysis of Phase 3 Pooled Data for Organons VTAMA (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 (Business Wire)
Jul-16-26 07:30AM	Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing (Business Wire)
Jul-07-26 08:00AM	Organon to Present New Analysis on VTAMA (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting (Business Wire)
Jun-25-26 01:58PM	Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-22-26 07:30AM	Organon Completes Agreement to License MIUDELLA, Sebela Pharmaceuticals Hormone-Free Intrauterine Device (Business Wire)
Jun-10-26 07:30AM	Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19 (Business Wire)
May-15-26 07:30AM	Organon to Present New Research on Access and Value at ISPOR 2026 (Business Wire)
May-14-26 05:25PM	Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? (PR Newswire)
05:00AM	Loading…
May-13-26 05:00AM	Indias pharma industry is going global. But can it catch up to China? (Pharma Voice)
May-07-26 04:52AM	Lilly, Gilead lead pharmas M&A boom (Pharma Voice)
May-04-26 02:55PM	Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-30-26 07:45AM	Organon: Q1 Earnings Snapshot (Associated Press)
07:30AM	Organon Reports Results for the First Quarter Ended March 31, 2026 (Business Wire)
Apr-29-26 10:00AM	European Commission (EC) Approves Henlius and Organon's POHERDY (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe (PR Newswire)
07:30AM	Organon Cancels First Quarter Earnings Call (Business Wire)
Apr-28-26 10:19AM	Micron initiated, Rambus downgraded: Wall Street's top analyst calls (The Fly)
04:00AM	As biosimilars gain US traction, patent thickets are under more scrutiny (Pharma Voice)
Apr-27-26 01:06PM	Shell acquiring Arc for $13.6B, China blocks Meta's bid for Manus AI (Yahoo Finance Video) +16.87%
01:01PM	Sun Pharma Joins the Big Table With Organon Acquisition (Moby)
11:24AM	Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders? (PR Newswire)
11:07AM	Budget airlines propose relief plan to Trump, Sun Pharma's $12B deal for Organon (Yahoo Finance Video)
09:37AM	Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm (The Wall Street Journal)
08:09AM	Sun Pharma to acquire Organon in $11.75 billion deal (Quartz)
08:09AM	Loading…
08:09AM	Sun Pharmaceutical is buying Organon in an $11.75 billion all-cash deal (Quartz)
06:16AM	Indias Sun Pharma Plots $12 Billion Organon Buyout For Global Reach (Bloomberg)
06:15AM	These Stocks Are Today's Movers: Qualcomm, Apple, Intel, Adidas, and More (Barrons.com)
06:11AM	Organon Jumps 15% as Sun Pharma Agrees $11.8bn Buyout (InvestorsHub)
05:57AM	Premarket movers: Organon, Qualcomm, Apple (MarketWatch)
05:50AM	Sun Pharma to acquire Organon for $11.75bn (Pharmaceutical Business Review)
05:22AM	Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. (Barrons.com)
01:19AM	Sun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal (Reuters)
Apr-26-26 09:53PM	India's Sun Pharma to buy US-listed Organon in $11.75 billion deal (Reuters)
09:16PM	Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion (The Wall Street Journal)
07:51PM	Sun Pharma signs Definitive Agreement to Acquire Organon (Business Wire)
Apr-24-26 01:09PM	Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma (Barrons.com) +30.93%
Apr-16-26 07:30AM	Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 (Business Wire)
Apr-15-26 07:30AM	Organons VTAMA (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis (Business Wire) +5.86%
Apr-10-26 02:43PM	Organon Jumps 25% As Report Cites $12 Billion Sun Pharma Offer (GuruFocus.com) +27.79%
10:01AM	This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. (Barrons.com)
09:25AM	This Womens Healthcare Stock Is Up 15% on Reports of a Takeover In the Works (Investopedia)
08:46AM	Organon climbs on report of takeover bid and more stocks on the move (MarketWatch)
Mar-27-26 08:00AM	Organon Debuts New Analysis of VTAMA (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age (Business Wire)
Mar-24-26 07:01AM	Organon: A High Cash Yield Hidden Behind Patent Fatigue (GuruFocus.com)
Mar-02-26 12:59PM	OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis (Zacks)
Feb-27-26 08:00AM	New Analysis of Organons VTAMA (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis (Business Wire)
Feb-23-26 04:37PM	Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% (Insider Monkey)
07:30AM	Organon Enters into Agreement to License MIUDELLA, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device (Business Wire)
Feb-19-26 12:39AM	5 Revealing Analyst Questions From Organon's Q4 Earnings Call (StockStory)
Feb-13-26 01:09AM	Organon & Co. Q4 Earnings Call Highlights (MarketBeat)
12:34AM	OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook (StockStory)
Feb-12-26 04:32PM	Organon & Co. Q4 2025 Earnings Call Summary (Moby) -8.19%
04:04PM	Organon & Co (OGN) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
10:30AM	Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:50AM	Organon (OGN) Misses Q4 Earnings and Revenue Estimates (Zacks)
08:01AM	Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations (StockStory)
07:51AM	Organon: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 (Business Wire)
Feb-10-26 10:05PM	Organon Earnings: What To Look For From OGN (StockStory)
Feb-02-26 05:50PM	Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jan-29-26 01:28PM	Organon Completes Divesture of JADA System to Laborie Medical (Zacks)
Jan-28-26 12:45PM	Organon Completes Divestiture of JADA System to Laborie (Business Wire)
Jan-27-26 05:50PM	Organon (OGN) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-22-26 06:46AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-21-26 06:00PM	Organon (OGN) Outperforms Broader Market: What You Need to Know (Zacks)
Jan-20-26 03:10PM	Why Are Organon (OGN) Shares Soaring Today (StockStory) +7.99%
11:04AM	Organon Secures FDA Approval Extending NEXPLANON Use to Five Years (Zacks)
10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-16-26 09:12PM	Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque (Business Wire)
08:53AM	JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency (Pharmaceutical Technology)
Jan-15-26 05:50PM	Organon (OGN) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jan-14-26 06:00PM	Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Jan-08-26 01:30AM	Organon Enters into a Commercialization Agreement for Daiichi Sankyos Nilemdo in France, Denmark, Iceland, Sweden, Finland and Norway (Business Wire)
Jan-05-26 06:00PM	Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing (Zacks) +8.47%
Dec-24-25 09:00AM	Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock (Zacks)
Dec-22-25 05:50PM	Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Dec-12-25 09:00AM	Is Trending Stock Organon & Co. (OGN) a Buy Now? (Zacks)
Dec-09-25 04:01PM	Why Organon (OGN) Shares Are Trading Lower Today (StockStory)
Dec-01-25 09:00AM	Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Nov-30-25 11:03PM	Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-25-25 10:32PM	Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks (StockStory) +6.37%
07:30AM	Organon To Present at the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
Nov-18-25 09:00AM	Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Nov-17-25 01:14PM	Henlius and Organon score first US Perjeta biosimilar approval (Pharmaceutical Technology)
05:30AM	Henlius and Organon Announce US FDA Approval of POHERDY (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US (Business Wire)
12:34AM	The 5 Most Interesting Analyst Questions From Organon's Q3 Earnings Call (StockStory)
Nov-11-25 12:50PM	Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends (Insider Monkey)
12:26PM	Organon (OGN) Stock Trades Down, Here Is Why (StockStory)
12:31AM	OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration (StockStory)
Nov-10-25 04:01PM	Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... (GuruFocus.com) +13.72%
01:30PM	Organon (OGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
10:06AM	Laborie inks $465M deal to buy post-childbirth device from Organon (MedTech Dive)
08:45AM	Organon (OGN) Q3 Earnings and Revenues Beat Estimates (Zacks)
08:01AM	Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q3 (StockStory)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Aug 11 '26	Option Exercise	0.00	11,519	0	41,566	Aug 12 01:01 PM
JULIANA P DRINANE	Officer	Aug 05 '26	Proposed Sale	13.57	14,761	200,307		Aug 05 04:26 PM
Drinane Juliana Papa	Head of Mfg & Supply	Aug 05 '26	Sale	13.57	14,761	200,307	18,475	Aug 05 04:04 PM
Holzbaur Lynette	Affiliate	May 06 '26	Proposed Sale	13.35	26,448	353,080		May 08 08:31 PM
Holzbaur Lynette	SVP and Corporate Controller	May 06 '26	Buy	13.35	26,448	353,080	52,851	May 07 10:02 AM
Drinane Juliana Papa	Interim Head of Mfg & Supply	Mar 31 '26	Option Exercise	0.00	16,451	0	36,687	Apr 02 04:26 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Mar 31 '26	Option Exercise	0.00	13,431	0	34,867	Apr 02 04:18 PM
Karp Daniel	Executive VP, Corp. Dev.	Mar 31 '26	Option Exercise	0.00	18,053	0	71,653	Apr 02 04:17 PM
Stahler Rachel A	Chief Information Officer	Mar 31 '26	Option Exercise	0.00	18,867	0	120,322	Apr 02 04:14 PM
WALSH MATTHEW M	Chief Financial Officer	Mar 31 '26	Option Exercise	0.00	33,593	0	220,126	Apr 02 04:13 PM
Falcione Aaron	Chief Human Resources Officer	Mar 31 '26	Option Exercise	0.00	17,925	0	105,265	Apr 02 04:11 PM
Weaver Kirke	Gen. Counsel & Corp. Secy.	Mar 31 '26	Option Exercise	0.00	18,513	0	96,147	Apr 02 04:09 PM
Nisita Vittorio	Head of Global Business Svcs	Mar 31 '26	Option Exercise	0.00	13,000	0	73,494	Apr 02 04:07 PM
Holzbaur Lynette	SVP and Corporate Controller	Mar 31 '26	Option Exercise	0.00	10,967	0	28,316	Apr 02 04:06 PM
Morrissey Joseph T. Jr.	Interim CEO	Mar 31 '26	Option Exercise	0.00	24,584	0	127,907	Apr 02 04:02 PM
Stahler Rachel A	Chief Information Officer	Mar 29 '26	Option Exercise	0.00	8,200	0	106,510	Mar 31 04:16 PM
Holzbaur Lynette	SVP and Corporate Controller	Mar 29 '26	Option Exercise	0.00	5,319	0	19,995	Mar 31 04:15 PM
Karp Daniel	Executive VP, Corp. Dev.	Mar 29 '26	Option Exercise	0.00	14,184	0	60,853	Mar 31 04:14 PM
Weaver Kirke	Gen. Counsel & Corp. Secy.	Mar 29 '26	Option Exercise	0.00	7,757	0	81,611	Mar 31 04:12 PM
Nisita Vittorio	Head of Global Business Svcs	Mar 29 '26	Option Exercise	0.00	5,762	0	64,046	Mar 31 04:11 PM
Drinane Juliana Papa	Interim Head of Mfg & Supply	Mar 29 '26	Option Exercise	0.00	7,979	0	25,154	Mar 31 04:10 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Mar 29 '26	Option Exercise	0.00	8,865	0	23,909	Mar 31 04:09 PM
Falcione Aaron	Chief Human Resources Officer	Mar 29 '26	Option Exercise	0.00	8,422	0	92,531	Mar 31 04:08 PM
WALSH MATTHEW M	Chief Financial Officer	Mar 29 '26	Option Exercise	0.00	15,071	0	195,822	Mar 31 04:06 PM
Morrissey Joseph T. Jr.	Interim CEO	Mar 29 '26	Option Exercise	0.00	9,752	0	108,323	Mar 31 04:05 PM
COX CARRIE SMITH	Executive Chair	Nov 12 '25	Buy	7.67	65,400	501,755	77,869	Nov 13 04:05 PM
Drinane Juliana Papa	Interim Head of Mfg & Supply	Nov 07 '25	Option Exercise	0.00	3,626	0	18,417	Nov 12 05:48 PM
Arjona Ferreira Juan Camilo	Head of R&D & CMO	Nov 07 '25	Option Exercise	0.00	6,446	0	31,223	Nov 10 04:14 PM
Holzbaur Lynette	SVP and Corporate Controller	Nov 07 '25	Option Exercise	0.00	2,417	0	15,365	Nov 10 04:04 PM
Holzbaur Lynette	SVP and Corporate Controller	Nov 05 '25	Option Exercise	0.00	3,037	0	13,814	Nov 06 04:11 PM

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Executive Chair of the BoardMs. Carrie Smith Cox

Chief Executive OfficerMr. Joseph T. Morrissey Jr.

Executive VP & CFOMr. Matthew M. Walsh C.F.A.

Executive VPMs. Rachel A. Stahler

Executive VPMr. Kirke Weaver

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Organon & Co

Upgrade your Finviz experience